EAU 2013 - Programme Book - YouMed

Sunday, 17 March - EAU Programme
Abstract Session
12.15 - 13.45 New methods in imaging and targeting prostate cancer
Brown Hall 1-2 - Level S2
Poster Session 30
Chairs: B.M. Carey, Leeds (GB)
J. Walz, Marseille (FR)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
350 Validation of histoscanning system to detect and characterize prostate cancer
A. Govorov, D. Pushkar, M. Kovylina, A. Vasilyev, T. Moiseenko (Moscow, Russia)
351 Prostate HistoScanning for assessment of tumour volume and pathological stage prior to radical
prostatectomy: What is its role in routine clinical practice?
S. Javed, E. Chadwick, S. Beveridge, S. Bott, C. Eden, S. Langley (Guildford, Frimley, United Kingdom)
352 Prostate histoscanning as a tool for decision making
P. Macek, E. Barret, R.E. Sanchez Salas, M. Galiano, F. Rozet, Y. Ahallal, J.M Gaya, M. Durand, L. Mascle,
C. Giedelman, L. Lunelli, X. Cathelineau (Paris, France)
* 353 Prostate histoscanning for the detection, localization and volume estimation of prostate cancer- PHS02
blind phase results
L.A.M. Simmons, HU Ahmed, F. Zát’ura, M. Winkler, J. Braeckman, I. Meiers, D. Nir, P. Autier, S. Charman,
M. Emberton (London, United Kingdom; Olomouc, Czech Republic; Brussels, Waterloo, Belgium; Lyon,
France)
354 CP OCT imaging of prostate neurovascular bundle
D. Ledyaev, V. Atduev, L. Shkalova, E. Zagaynova (Nizhny Novgorod, Russia)
355 Parametric diffusion weighted imaging at 3 tesla accurately predicts histological outcomes in men
presenting for a TRUS-guided biopsy of the prostate
D.C. Moran, L. Marignol, A. Perry, A. Fagan, E. Gaffney, J.F. Meaney, D. Hollywood, T.H. Lynch (Dublin,
Ireland)
356 Does 3 Tesla endorectal PET/MRI change the operative tactics in prostate cancer?
J. Klein, J. Hauser, J-P. Vallee, C. Iselin (Geneva, Switzerland)
357 Choline positron emission tomography (PET) or PET/computed tomography (CT) and biochemical relapse of
prostate cancer (PCa): A meta-analysis of literature
A. Guttilla, F. Zattoni, L. Evangelista, G. Saladini, F. Zattoni (Padua, Italy)
* 358 PET-CT in recurrent prostate cancer
D.K. Osmonov, A.V. Aksenov, D. Heimann, C.M. Naumann, K-P. Jünemann (Kiel, Germany)
359 Identification of apparent-diffusion-coefficient (ADC) cut-offs during DWI-MRI in prostate cancer lymph
node metastasis: Implication for daily clinical practice
L. Budäus, S-R. Leyh-Bannurah, C. Seiwerts, B. Beyer, G. Salomon, H. Heinzer, M. Graefen, G. Adam,
M. Regier (Hamburg, Germany)
EAU Milan 2013
175
Sunday